Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$615M |
| 2 |
Uber
UBER
|
+$551M |
| 3 |
Expedia Group
EXPE
|
+$523M |
| 4 |
PayPal
PYPL
|
+$452M |
| 5 |
Eaton
ETN
|
+$408M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$681M |
| 2 |
RTN
Raytheon Company
RTN
|
+$543M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$537M |
| 4 |
Charter Communications
CHTR
|
+$472M |
| 5 |
SPDR Gold Trust
GLD
|
+$464M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 5.14% |
| 2 | Financials | 4.52% |
| 3 | Industrials | 4.17% |
| 4 | Healthcare | 3.91% |
| 5 | Consumer Discretionary | 3.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
8101
Immersion
IMMR
$252M
| $174K | ﹤0.01% |
23,453
-28,010
| -54% | -$210K |
|
|
QTNT
8102
CALL
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $174K | ﹤0.01% |
458
+153
| +50% | +$50.7K |
|
8103
CALL
BioLife Solutions
BLFS
$1.7B
| $173K | ﹤0.01% |
+10,700
| New | +$174K |
|
|
IMGN
8104
PUT
DELISTED
Immunogen Inc
IMGN
| $173K | ﹤0.01% |
33,900
+12,000
| +55% | +$40.7K |
|
8105
CALL
American Superconductor
AMSC
$1.59B
| $172K | ﹤0.01% |
21,900
-12,000
| -35% | -$96.7K |
|
8106
CALL
Voyager Therapeutics
VYGR
$201M
| $172K | ﹤0.01% |
12,300
-3,500
| -22% | -$50.9K |
|
|
SPNE
8107
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $172K | ﹤0.01% |
+14,305
| New | +$175K |
|
8108
Aldeyra Therapeutics
ALDX
$93.5M
| $171K | ﹤0.01% |
29,363
+12,148
| +71% | +$70.2K |
|
|
ENZ
8109
DELISTED
Enzo Biochem, Inc.
ENZ
| $171K | ﹤0.01% |
64,993
-53,523
| -45% | -$160K |
|
8110
Grupo Aval
AVAL
$6.01B
| $170K | ﹤0.01% |
+19,519
| New | +$157K |
|
8111
CALL
1-800-Flowers.com
FLWS
$258M
| $170K | ﹤0.01% |
11,700
-600
| -5% | -$8.15K |
|
8112
CALL
Talphera
TLPH
$74.2M
| $170K | ﹤0.01% |
4,035
+1,560
| +63% | +$63.7K |
|
|
BCLI
8113
CALL
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $169K | ﹤0.01% |
+2,633
| New | +$153K |
|
8114
PUT
Kosmos Energy
KOS
$1.48B
| $169K | ﹤0.01% |
+29,600
| New | +$179K |
|
|
RWT
8115
PUT
Redwood Trust
RWT
$594M
| $169K | ﹤0.01% |
+10,200
| New | +$168K |
|
8116
ADMA Biologics
ADMA
$2.22B
| $168K | ﹤0.01% |
41,907
-6,904
| -14% | -$30.1K |
|
8117
Seres Therapeutics
MCRB
$48.4M
| $168K | ﹤0.01% |
2,437
+1,542
| +172% | +$114K |
|
|
YRD
8118
Yiren Digital
YRD
$110M
| $168K | ﹤0.01% |
30,286
-3,459
| -10% | -$20.3K |
|
8119
PUT
Ardelyx
ARDX
$997M
| $167K | ﹤0.01% |
22,200
+2,400
| +12% | +$14.6K |
|
|
CLSD
8120
DELISTED
Clearside Biomedical
CLSD
| $167K | ﹤0.01% |
+3,839
| New | +$80.7K |
|
8121
CALL
Harrow
HROW
$1.51B
| $167K | ﹤0.01% |
21,500
+1,900
| +10% | +$11K |
|
|
8122
PUT
Harrow
HROW
$1.51B
| $167K | ﹤0.01% |
21,500
+700
| +3% | +$4.05K |
|
8123
PUT
abrdn Physical Gold Shares ETF
SGOL
$7.41B
| $167K | ﹤0.01% |
11,400
-56,600
| -83% | -$809K |
|
|
AGS
8124
PUT
DELISTED
PlayAGS
AGS
| $166K | ﹤0.01% |
13,700
+800
| +6% | +$9.13K |
|
8125
NCS Multistage Holdings
NCSM
$125M
| $166K | ﹤0.01% |
3,958
-1,547
| -28% | -$67.6K |
|
Similar funds
Citadel Advisors's Q4 2019 Portfolio in Review
As of Q4 2019, Citadel Advisors held 10,299 positions worth $230B, up 8.7% from $212B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Citadel Advisors withdrew a net $8.18B in Q4 2019, closing 1,266 positions and reducing 4,117 holdings. Its most notable exit was Celgene Corp, an estimated $681M position sold in full.
By sector, the portfolio is most concentrated in Technology at 5.1% of assets, down from 5.3% a quarter earlier, followed by Financials and Industrials.
Against the trend, Citadel Advisors opened a new position in Interxion Holding N.V. worth $83.9M.
- Citadel Advisors's largest Q4 2019 buy was Interxion Holding N.V.: 1,000,931 shares worth $83.9M.
- Citadel Advisors added most to Amazon in Q4 2019, an estimated $615M increase.
- Citadel Advisors's biggest Q4 2019 reduction was Raytheon Company, cutting an estimated $543M.
- Citadel Advisors fully exited Celgene Corp in Q4 2019, selling an estimated $681M.
- Citadel Advisors's ten largest holdings make up 23% of its $230B portfolio in Q4 2019.
- Citadel Advisors opened 1,220 new positions and closed 1,266 in Q4 2019.
- Citadel Advisors's portfolio value rose 8.7% quarter-over-quarter to $230B.
Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.